Skip to content

What is the Optimal antiplatElet & anticoagulant therapy in patients with oral anticoagulation and coronary StenTing

What is the Optimal antiplatElet & anticoagulant therapy in patients with oral anticoagulation and coronary StenTing - WOEST Trial:

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON35700
Enrollment
496
Registered
2008-09-16
Start date
2008-05-01
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation = Heart rhythm disorder

Interventions

only patients sceduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antit

Sponsors

Sint Antonius Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patient under warfarin treatment such as patients with atrial fibrillation, mechanical valve... AND with indication for percutaneous coronary intervention

Exclusion criteria

Exclusion criteria: cardiogenic shock, contra-indication for aspirin or clopidogrel, documented peptic ulcer disease within the previous six months, pregnancy and previous intracerebral haemorrhage or significant thrombocytopenia (platelet count

Design outcomes

Primary

MeasureTime frame
The combined end point of minor, moderate or major bleeding complications during the initial hospitalization & one year follow-up.

Secondary

MeasureTime frame
The combined event of death, myocardial infarction, stroke, systemic embolisation & target vessel revascularisation and the individual components of the composite primary and secondary endpoints.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)